Drug Trials
JavaScript or Flash Player Not Detected
This ALS banner requires Flash player 7 or higher or javascript.
PLEASE NOTE:
As of November 23, 2009, ALS Canada has a new address and phone number:
3000 Steeles Avenue East, Suite 200
Markham, Ontario L3R 4T9
Phone: 905-248-2052   Fax: 905-248-2019

Drug Trials

For more information on the Lithium Trial please visit:
www.als.ca/research/lithium_trial.aspx 

News of drug treatments and trials will also be announced through our news network. 

If you want to be on our e-mail list, please sign up.
Drug Trial News - The latest ALS drug trial articles.
1.  Stage 3 ceftriaxone trial begins

A stage 3 trial has begun studying the efficacy of ceftriaxone, to see if it prolongs survival and/or slows decline in function in patients living with ALS. ◊

"Stage 3 ceftriaxone trial begins"
2.  Study Reports That Lithium Delays Progression of ALS

Italian researchers recently published a ground-breaking study that indicated that the drug lithium delayed ALS progression in a small group of patients ◊

"Study Reports That Lithium Delays Progression of ALS"
3.  Statement On Three Drug Therapies

A meeting of the Canadian Phase IV Riluzole Study (ALS-601) Steering Committee was recently convened to discuss the use of Riluzole-Nimodipine-Minocycline combination therapy in the treatment of ALS ◊

"Statement On Three Drug Therapies"
4.  Novartis ALS Trial - Closes July 15th

Recruitment for the Novartis ALS trial (TCH102) will close on July 15th. There are plans for more trials with the compound TCH346, although the results from the 102 trial will be required before goin ◊

"Novartis ALS Trial - Closes July 15th"
5.  Drug Trial Information - An Article

Seminars in Neurology [Sem Neurology 21(2):167-175, 2000. © 2000 Thieme Medical Publishers, Inc.] Thieme Medical Publishers, Inc. is the exclusive copyright holder of this work and therefore direct ◊

"Drug Trial Information - An Article"